MXPA06014768A - Analogos de epitopes. - Google Patents
Analogos de epitopes.Info
- Publication number
- MXPA06014768A MXPA06014768A MXPA06014768A MXPA06014768A MXPA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A
- Authority
- MX
- Mexico
- Prior art keywords
- analogs
- residues
- mhc
- epitope analogs
- norvaline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Algunas modalidades se refiere a analogos de peptidos que corresponden a epitopes de celulas T de MHC restringido clase I y a los metodos para su generacion. Estos analogos pueden contener sustituciones de aminoacidos en residuos que interactuan directamente con las moleculas MHC, y pueden conferir propiedades inmunologicas mejoradas, modificadas o utiles. Adicionalmente, se describen clases de analogos, en los cuales las diversas sustituciones comprenden los residuos no estandar de norleucina y/o norvalina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58100104P | 2004-06-17 | 2004-06-17 | |
US58096204P | 2004-06-17 | 2004-06-17 | |
PCT/US2005/021609 WO2006009920A2 (en) | 2004-06-17 | 2005-06-17 | Epitope analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06014768A true MXPA06014768A (es) | 2007-06-22 |
Family
ID=35198081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA06014768A MXPA06014768A (es) | 2004-06-17 | 2005-06-17 | Analogos de epitopes. |
Country Status (10)
Country | Link |
---|---|
US (5) | US20060057673A1 (es) |
EP (2) | EP1765858B1 (es) |
JP (2) | JP5166025B2 (es) |
KR (2) | KR20100092031A (es) |
AU (1) | AU2005265182B2 (es) |
CA (1) | CA2571168A1 (es) |
IL (2) | IL180101A (es) |
MX (1) | MXPA06014768A (es) |
SG (1) | SG153827A1 (es) |
WO (1) | WO2006009920A2 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US7178491B2 (en) * | 2003-06-05 | 2007-02-20 | Caterpillar Inc | Control system and method for engine valve actuator |
US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
JP2008503494A (ja) * | 2004-06-17 | 2008-02-07 | マンカインド コーポレイション | 診断方法を治療方法と統合することによる免疫療法の効力改善 |
AU2005265182B2 (en) | 2004-06-17 | 2012-06-21 | Mannkind Corporation | Epitope analogs |
AU2005321905A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass CD+4 cells in the induction of an immune response |
AU2005321940B2 (en) | 2004-12-29 | 2012-04-19 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
JP2008526760A (ja) | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用 |
CN101146550B (zh) * | 2004-12-29 | 2013-04-17 | 曼康公司 | 免疫原性组合物用于制备引发和增强免疫应答的试剂盒的用途 |
AU2006259307B2 (en) | 2005-06-17 | 2012-12-20 | Mannkind Corporation | Epitope analogues |
US8084592B2 (en) * | 2005-06-17 | 2011-12-27 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
MX2007015933A (es) | 2005-06-17 | 2008-04-21 | Mannkind Corp | Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales. |
US8706421B2 (en) * | 2006-02-16 | 2014-04-22 | Microsoft Corporation | Shift-invariant predictions |
US20070192033A1 (en) * | 2006-02-16 | 2007-08-16 | Microsoft Corporation | Molecular interaction predictors |
US8396671B2 (en) * | 2006-02-16 | 2013-03-12 | Microsoft Corporation | Cluster modeling, and learning cluster specific parameters of an adaptive double threading model |
CN1850855B (zh) * | 2006-05-26 | 2012-08-29 | 厦门大学 | 用于免疫或制备单克隆抗体的方法和组合物 |
AU2007272785A1 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes |
ES2601432T3 (es) | 2006-08-11 | 2017-02-15 | Life Sciences Research Partners Vzw | Péptidos inmunógenos y su uso en trastornos inmunitarios |
US8121797B2 (en) * | 2007-01-12 | 2012-02-21 | Microsoft Corporation | T-cell epitope prediction |
WO2008100598A2 (en) * | 2007-02-15 | 2008-08-21 | Mannkind Corporation | A method for enhancing t cell response |
CA2996732C (en) | 2007-03-26 | 2020-10-27 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Prame derived peptides and immunogenic compositions comprising these |
MX2009012635A (es) * | 2007-05-23 | 2012-09-13 | Mannkind Corp | Vectores multicistronicos y metodos para su diseño. |
ES2676630T3 (es) | 2008-02-14 | 2018-07-23 | Life Sciences Research Partners Vzw | Control inmunogénico de tumores y células tumorales |
CA2778707A1 (en) | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
CN102869682B (zh) | 2009-11-18 | 2016-10-19 | 曼康公司 | 单克隆抗体及其诊断用途 |
TWI565473B (zh) | 2010-03-11 | 2017-01-11 | 腫瘤療法 科學股份有限公司 | Hjurp胜肽與含此胜肽之疫苗 |
US9109007B2 (en) | 2010-08-18 | 2015-08-18 | Purdue Pharma L.P. | MHC-I restricted epitopes containing non-natural amino acid residues |
ES2734889T3 (es) | 2010-09-21 | 2019-12-12 | Us Health | Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso |
HUE055070T2 (hu) | 2010-11-25 | 2021-10-28 | Imnate Sarl | Immunogén peptidek fertõzõ betegségek, autoimmun betegségek, allofaktorokra adott immunválaszok, allergiás betegségek, tumorok, graftkilökõdés, és génterápiához vagy génvakcinációhoz alkalmazott vírusvektorokkal szembeni immunválaszok megelõzésében és/vagy kezelésében történõ alkalmazásra |
WO2012076059A1 (en) * | 2010-12-09 | 2012-06-14 | Stichting Het Nederlands Kanker Instituut | Immune restricted peptides with increased efficacy |
EP2654779B1 (en) | 2010-12-23 | 2018-02-28 | Ludwig Institute for Cancer Research, Ltd. | Liposomal formulation of nonglycosidic ceramides and uses thereof |
GB201201511D0 (en) * | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
WO2020051566A1 (en) * | 2018-09-07 | 2020-03-12 | Immunotope, Inc. | Vaccines with enhanced immune response and methods for their preparation |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5241047A (en) * | 1988-12-08 | 1993-08-31 | Biochem Pharma Inc. | Synthetic peptides and mixtures thereof for detecting HIV antibodies |
US6417165B1 (en) | 1988-03-27 | 2002-07-09 | Ludwig Institute For Cancer Research | NY-ESO-1-peptide derivatives, and uses thereof |
US5804381A (en) * | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
DE4128684A1 (de) * | 1991-08-29 | 1993-03-04 | Behringwerke Ag | Hcmv-spezifische peptide, mittel dazu und ihre verwendung |
US5662907A (en) * | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
WO1994009820A1 (en) | 1992-11-05 | 1994-05-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US5747271A (en) * | 1992-12-22 | 1998-05-05 | Ludwig Institute For Cancer Research | Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals |
US5620886A (en) * | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
US5935818A (en) * | 1995-02-24 | 1999-08-10 | Sloan-Kettering Institute For Cancer Research | Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof |
US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
US6025191A (en) | 1995-06-07 | 2000-02-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof |
US5821122A (en) * | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
US6548064B1 (en) * | 1997-05-05 | 2003-04-15 | Ludwig Institute For Cancer Research | Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules |
US6025470A (en) * | 1997-06-23 | 2000-02-15 | Ludwig Institute For Cancer Research | Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof |
EP1003548B1 (en) | 1997-07-10 | 2006-05-10 | Mannkind Corporation | Device for inducing a ctl response |
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US6994851B1 (en) * | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
US6576755B1 (en) * | 1997-09-10 | 2003-06-10 | Zymogenetics, Inc. | Beta-defensins |
US6709844B1 (en) * | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
US20030138808A1 (en) | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
US20020072493A1 (en) | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
US6777388B1 (en) * | 1998-08-21 | 2004-08-17 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
GB9818938D0 (en) * | 1998-08-28 | 1998-10-21 | Alpharma As | Bioactive peptides |
CA2361658C (en) * | 1999-02-05 | 2013-04-09 | The University Of Melbourne | T helper cell epitopes |
US7157091B1 (en) * | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
EP1286590A4 (en) * | 1999-11-05 | 2005-05-11 | Axonyx Inc | PEPTIDE ANALOGUES AND MIMETICS MAY BE USED IN VIVO TO TREAT DISEASES ASSOCIATED WITH AMYLOID OR PSEUDO-AMYLOID PROTEIN ABNORMAL REPLIAGE OR THEIR PATHOLOGICAL PRECURSOR RICH IN BETA-LEAF |
AU776058B2 (en) * | 1999-11-15 | 2004-08-26 | Chancellor, Masters And Scholars Of The University Of Oxford, The | NY-ESO-1 nonapeptide derivatives, and uses thereof |
US6605711B1 (en) * | 1999-11-15 | 2003-08-12 | Ludwig Institute For Cancer Research | NY-ESO-1 peptide derivatives, and uses thereof |
EP1230268B1 (en) * | 1999-11-18 | 2009-10-14 | Pharmexa Inc. | Heteroclitic analogs of class i epitopes |
EP1118860A1 (en) * | 2000-01-21 | 2001-07-25 | Rijksuniversiteit te Leiden | Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes |
CA2400215A1 (en) | 2000-02-23 | 2001-08-30 | Epimmune Inc. | Hla binding peptides and their uses |
EP1272509A2 (en) * | 2000-04-05 | 2003-01-08 | V.I. Technologies, Inc. | Prion-binding peptidic ligands and methods of using same |
US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
CN100589845C (zh) * | 2001-03-07 | 2010-02-17 | 麦康公司 | 用于治疗癌症的抗新血管系统制剂 |
WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
US20030148973A1 (en) * | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
US20030017134A1 (en) | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
ES2358642T3 (es) * | 2001-11-07 | 2011-05-12 | Mannkind Corporation | Vectores de expresión que codifican epítopos de antígenos y métodos para su diseño. |
WO2003104428A2 (en) * | 2002-01-21 | 2003-12-18 | Vaccinex, Inc. | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
US20060128607A1 (en) * | 2002-01-29 | 2006-06-15 | Anja-Katrin Bosserhoff | Method for inhibiting "melanoma inhibitory activity" mia |
US6992176B2 (en) * | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
EP1482963A4 (en) | 2002-03-08 | 2010-06-09 | Univ Texas | CONTROLLED MODULATION OF LATERAL CHAIN LENGTH OF AMINO ACIDS OF ANTIGENS PEPTIDES |
US20070105779A1 (en) * | 2002-07-31 | 2007-05-10 | Danila Valmori | Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof |
AU2003256912A1 (en) * | 2002-08-16 | 2004-03-03 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
CA2496888A1 (en) | 2002-09-06 | 2004-03-18 | Mannkind Corporation | Epitope sequences |
AU2003294220A1 (en) * | 2002-09-17 | 2004-04-23 | Antigen Express, Inc. | Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES |
AU2004253479B9 (en) * | 2003-06-17 | 2011-10-06 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
US20050118186A1 (en) * | 2003-06-17 | 2005-06-02 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in compositions for various types of cancers |
US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
JP2008503494A (ja) * | 2004-06-17 | 2008-02-07 | マンカインド コーポレイション | 診断方法を治療方法と統合することによる免疫療法の効力改善 |
US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
AU2005265182B2 (en) * | 2004-06-17 | 2012-06-21 | Mannkind Corporation | Epitope analogs |
CN101146550B (zh) * | 2004-12-29 | 2013-04-17 | 曼康公司 | 免疫原性组合物用于制备引发和增强免疫应答的试剂盒的用途 |
JP2008526760A (ja) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用 |
AU2005321940B2 (en) * | 2004-12-29 | 2012-04-19 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
US9469902B2 (en) | 2014-02-18 | 2016-10-18 | Lam Research Corporation | Electroless deposition of continuous platinum layer |
EP3636238B1 (en) | 2018-10-12 | 2021-04-28 | Liko Research & Development AB | Gates with transition ramps for overhead lifting rails |
-
2005
- 2005-06-17 AU AU2005265182A patent/AU2005265182B2/en not_active Ceased
- 2005-06-17 EP EP05762506A patent/EP1765858B1/en not_active Not-in-force
- 2005-06-17 JP JP2007516810A patent/JP5166025B2/ja not_active Expired - Fee Related
- 2005-06-17 WO PCT/US2005/021609 patent/WO2006009920A2/en active Application Filing
- 2005-06-17 KR KR1020107013889A patent/KR20100092031A/ko not_active Application Discontinuation
- 2005-06-17 SG SG200904127-8A patent/SG153827A1/en unknown
- 2005-06-17 EP EP10180780.8A patent/EP2332971B1/en not_active Not-in-force
- 2005-06-17 US US11/156,369 patent/US20060057673A1/en not_active Abandoned
- 2005-06-17 KR KR1020077001143A patent/KR20070056042A/ko not_active Application Discontinuation
- 2005-06-17 MX MXPA06014768A patent/MXPA06014768A/es active IP Right Grant
- 2005-06-17 CA CA002571168A patent/CA2571168A1/en not_active Abandoned
- 2005-06-17 US US11/155,929 patent/US8354380B2/en not_active Expired - Fee Related
- 2005-06-17 US US11/156,253 patent/US8202841B2/en not_active Expired - Fee Related
-
2006
- 2006-12-14 IL IL180101A patent/IL180101A/en not_active IP Right Cessation
-
2008
- 2008-06-13 JP JP2008155749A patent/JP2008283979A/ja not_active Ceased
-
2010
- 2010-12-09 IL IL209859A patent/IL209859A0/en unknown
-
2011
- 2011-02-28 US US13/037,350 patent/US20110301327A1/en not_active Abandoned
-
2013
- 2013-01-14 US US13/741,232 patent/US20130195901A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2006009920A2 (en) | 2006-01-26 |
JP2008510453A (ja) | 2008-04-10 |
JP2008283979A (ja) | 2008-11-27 |
CA2571168A1 (en) | 2006-01-26 |
US8354380B2 (en) | 2013-01-15 |
US20060094661A1 (en) | 2006-05-04 |
EP1765858B1 (en) | 2012-11-21 |
EP2332971B1 (en) | 2016-02-17 |
US20110301327A1 (en) | 2011-12-08 |
IL209859A0 (en) | 2011-02-28 |
AU2005265182B2 (en) | 2012-06-21 |
EP2332971A1 (en) | 2011-06-15 |
US20130195901A1 (en) | 2013-08-01 |
US20060057673A1 (en) | 2006-03-16 |
US20060063913A1 (en) | 2006-03-23 |
IL180101A (en) | 2014-02-27 |
WO2006009920A3 (en) | 2006-06-15 |
AU2005265182A1 (en) | 2006-01-26 |
SG153827A1 (en) | 2009-07-29 |
KR20100092031A (ko) | 2010-08-19 |
IL180101A0 (en) | 2007-05-15 |
KR20070056042A (ko) | 2007-05-31 |
US8202841B2 (en) | 2012-06-19 |
EP1765858A2 (en) | 2007-03-28 |
JP5166025B2 (ja) | 2013-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG153827A1 (en) | Epitope analogs | |
WO2006138562A3 (en) | Epitope analogues | |
MX338940B (es) | Identificacion de epitopos ige novedosos. | |
AR117007A2 (es) | Región constante de anticuerpo mutante | |
HK1197250A1 (en) | Regulatory cell epitopes, compositions and uses hereof | |
NZ593833A (en) | Extended recombinant polypeptides and compositions comprising same | |
MX2023002858A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
HK1205193A1 (en) | Recombinant n-glycosylated proteins from procaryotic cells n- | |
SI1948789T1 (sl) | Postopek za pridobivanje permanentnih humanih celičnih linij | |
NZ595825A (en) | Antibody containing igg2 having amino acid mutation introduced therein | |
NZ618391A (en) | Antigenic tau peptides and uses thereof | |
WO2007051063A3 (en) | Gpcr expressing cell lines and antibodies | |
MX2007015935A (es) | Agentes y metodos basados en el uso del dominio eda de la fibronectina. | |
EP2403871A4 (en) | SPECIFIC ANTIBODIES AND EPITOPES OF A PRION PROTEIN | |
MX2009012420A (es) | Reovirus mutantes y metodos para elaboracion y uso. | |
PE20121564A1 (es) | Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas | |
BRPI0508916A (pt) | polipeptìdeos hìbridos imunogênicos antiobesidade e composição de vacina antiobesidade compreendendo-os | |
PL372862A1 (en) | T-cell epitopes in erythropoietin | |
WO2007089038A8 (ja) | 新規ホスホリパーゼd | |
NZ592461A (en) | Rab6kifl/kif20a epitope peptide and vaccines containing the same | |
MX2020011298A (es) | Composiciones de antígeno micobacteriano y métodos de uso. | |
LT2005043A (en) | Process for preparing monoclonal antibodies; hybridoma cell lines generated by this process and recombinant chimeric virus-like particles with inserted foreign protein fragments as immunogenes to generate hybridomas by this process | |
PE20190967A1 (es) | Aislados modificados de streptomyces fungicidicus y su uso | |
UA100692C2 (ru) | Днк-плазмиды, имеющие повышенную экспрессию и стабильность | |
EP2504029A4 (en) | COMPOSITIONS, METHODS AND USES FOR THE EXPRESSION OF PEPTIDES ASSOCIATED WITH ENTEROBACTERIA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |